Literature DB >> 20872716

Clinical characteristics of hepatitis E in a "Non-Endemic" population.

Jeff Turner1, Andrew Godkin, Peter Neville, Jerry Kingham, Chin Lye Ch'ng.   

Abstract

Hepatitis E virus (HEV) is a ribonucleic acid (RNA) virus with predominant fecal oral spread. Traditionally in Western Europe it is associated with travel to endemic countries, but an increasing number of locally acquired cases have been reported throughout England. Patients presenting with acute non-travel associated HEV infection in south Wales over a 25-month period were monitored, in an attempt to understand the clinical picture and epidemiology in our patient population. Twenty-four patients were identified with non-travel associated HEV infection and studied prospectively. Patient demographics, symptoms, and serial laboratory results were recorded. There was a male/female ratio of 3:1, with a median patient age of 65.5 years old. Patients developed a significant icteric hepatitis (median peak bilirubin: 139 µmol/L, median peak AST: 1,973 IU/L and ALT: 2,021 IU/L), with liver function remaining abnormal for ∼7 weeks. All patients in whom HEV RNA was isolated were infected with genotype 3. Forty-six percent of patients presented during winter months. The data show a group mortality rate of 4.2%, similar to that reported in endemic countries. HEV results in a severe and occasionally fatal hepatitis. Testing for hepatitis E is now recommended in any patient presenting with acute hepatitis of unknown etiology.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872716     DOI: 10.1002/jmv.21905

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Prevalence of hepatitis E virus-specific antibodies in humans with occupational exposure to pigs.

Authors:  Andi Krumbholz; Ulrich Mohn; Jeannette Lange; Manfred Motz; Jürgen J Wenzel; Wolfgang Jilg; Mario Walther; Eberhard Straube; Peter Wutzler; Roland Zell
Journal:  Med Microbiol Immunol       Date:  2011-07-20       Impact factor: 3.402

2.  A Proline-Rich Domain in the Genotype 4 Hepatitis E Virus ORF3 C-Terminus Is Crucial for Downstream V105DLP108 Immunoactivity.

Authors:  Heng Wang; Fangxiao Ji; Huanbin Liang; Honglang Gu; Zhangyong Ning; Rongchang Liu; Guihong Zhang
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

3.  Hepatitis E virus seroprevalence among the general population in a livestock-dense area in the Netherlands: a cross-sectional population-based serological survey.

Authors:  Arianne B van Gageldonk-Lafeber; Wim van der Hoek; Floor Borlée; Dick J J Heederik; Sofie H Mooi; Catharina B M Maassen; C Joris Yzermans; Barry Rockx; Lidwien A M Smit; Johan H J Reimerink
Journal:  BMC Infect Dis       Date:  2017-01-05       Impact factor: 3.090

4.  A Case of Acute Hepatitis E Infection in a Patient with Non-Hodgkin Lymphoma Treated Successfully with Ribavirin.

Authors:  Hasan N Y Haboubi; Rizwan Diyar; Ann Benton; Chin Lye Ch'ng
Journal:  Case Rep Gastrointest Med       Date:  2017-01-15

5.  An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population.

Authors:  Annatina Schnegg; Philippe Bürgisser; Cyril André; Alain Kenfak-Foguena; Giorgia Canellini; Darius Moradpour; Florence Abravanel; Jacques Izopet; Matthias Cavassini; Katharine E A Darling
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

6.  Serological investigation for hepatitis E virus infection in the patients with chronic maintenance hemodialysis from southwest of Iran.

Authors:  Omid R Zekavat; Alireza Makarem; Mohammad Y Karami; Aida Amanat; Maesoomeh Mohandes; Mojtaba Habibagahi
Journal:  Asian J Transfus Sci       Date:  2013-01

Review 7.  Hepatitis E virus infections in humans and animals.

Authors:  Young-Jo Song; Woo-Jung Park; Byung-Joo Park; Joong-Bok Lee; Seung-Yong Park; Chang-Seon Song; Nak-Hyung Lee; Kun-Ho Seo; Young-Sun Kang; In-Soo Choi
Journal:  Clin Exp Vaccine Res       Date:  2013-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.